reported a 27% increase in adjusted first-quarter earnings, but sales of its multiple sclerosis drug Tysabri fell short of Wall Street expectations.
The Cambridge, Mass-based biotech firm reported first-quarter net income of $244 million, or 84 cents a share, compared to net income of $163 million, or 54 cents a share in the year-earlier period.
On an adjusted basis, Biogen earned $1.05 a share, 4 cents better than the consensus estimate per Thomson Reuters.
First-quarter revenue rose 10% to $1.04 billion from $942.2 million one year ago, shy of the consensus forecast of $1.07 billion.
Worldwide sales of the multiple sclerosis drug Tysabri totaled $227 million in the first quarter, short of the consensus estimate of $246 million.
Approximately 2,200 new patients, or about 169 patients per week, began taking Tysabri in the first quarter, a bit lower than investors were expecting.
During the fourth quarter of 2008, Biogen said it was adding about 177 new Tysabri patients per week.
Last month, Biogen executies laid out plans to
, including new research into treatments that could potentially reverse the effects of PML. The company has also pointed to internal market research showing a large percentage of neurologists expect to increase use of Tysabri over the next six months while only a small percentage of doctors plan to prescribe less Tysabri.
Biogen shares Tysabri revenue with Irish drug maker
. Biogen recognized $165 million in revenue from Tysabri in the first quarter.
First-quarter sales of the multiple sclerosis drug Avonex rose 4% to $555 million, while Biogen recorded $279 million in revenue for its portion of sales of the cancer drug Rituxan, co-marketed by Genentech (now owned by Roche),
Biogen management is engaged in a proxy fight with financier Carl Icahn, who owns 5.4% of the company and is trying to seat his own slate of directors to the company's board. Icahn has stated publicly that he'd like to see Biogen sold.
Biogen shares were closed Thursday at $51.49.
Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;
to send him an email.